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Abstract: This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma 
extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These 
experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters 
for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, 
Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than 
half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed 
by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized 
controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a 
potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits 
for articular mobility, pain, and quality of life. 
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INTRODUCTION 
 For centuries, Curcuma has been used in Ayurvedic 
medicine for the treatment of digestive and painful disorders. Its 
indications have been enlarged to include multiple myeloma, 
pancreatic cancer, myelodysplasic syndromes, colon cancer, and 
psoriasis, among other disease conditions [1]. Investigators have 
isolated a series of curcuminoids containing 90% curcumin or 
diferuloylmethane, a polyphenolic pigment from the rhizoma of 
the plant with demonstrated antioxidant properties [2]. 
Epidemiological studies have suggested that curcumin 
possesses anti-inflammatory, hypolipemic, anti-thrombotic, 
anti-tumor, anti-diabetic, and neuroprotective properties [3]. 
Today, with more than 5,600 pharmacological studies, the 
potential applications of curcumin is documented in rheumatic, 
traumatic, and sport-related conditions, as well as Alzheimer’s 
disease, gastric ulcer, irritable colon disorder, and Crohn disease 
[4]. 
 Curcumin acts at various levels of the inflammation 
cascade; it modulates pro-inflammatory interleukin production 
and decreases the action of phospholipase A2, cyclooxygenase-
2, and 5-lipoxygenase. Curcumin does not affect Cox-1 activity, 
which contributes to its excellent tolerance. Its anti-
inflammatory action is due to its modulation of NFκB (anti-
catabolic activity) and other transcription factors [5]. In vitro 
studies have revealed a protective effect of curcumin on 
cartilage [6]. Taken together, these lines of evidence support the 
use of curcumin for the treatment of rheumatic conditions. 
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 However, the use of curcumin is limited by its low 
bioavailability. After oral administration, only a limited amount 
of the molecule penetrates the intestinal barrier to reach the 
circulation and the periphery of the body; the use of the native 
form of curcumin is therefore limited [7] To overcome these 
obstacles, Tilman SA, a Belgian pharmaceutical company, 
patented a new curcumin formulation called Flexofytol®. This 
innovative and licensed galenic form of curcumin uses a very 
thin dispersion of curcumin in a specific excipient and in the 
presence of emulsifiers that facilitate penetration through the 
intestinal barrier. Accordingly, the administration of 42 mg of 
this optimized curcumin preparation in a small capsule is equal 
to the ingestion of 57 g of native curcumin or 1 kg of Curcuma 
powder [6]. 
 This new curcumin preparation has been marketed in 
Belgium for more than 3 years and is one of the most 
frequently prescribed compounds for osteoarthritis. It is 
recommended for maintaining articular flexibility, 
preserving the joints, limiting cartilage ageing, and 
improving articular function, particularly for sensitive joints 
and tendons. Flexofytol® is registered not as a drug, but as a 
food supplement. 
 We sought to perform a real-life evaluation of patient 
satisfaction with Flexofytol®. The present study was 
performed in 2013 with the help of general practitioners, 
with the goal of assessing their personal experience with 
patients suffering various manifestations of osteoarthritis. 
This investigation also aimed to evaluate the potential 
benefits of Flexofytol® on joint function, to identify the 
treatment period required before clinical improvement 
becomes apparent, to pinpoint undesirable effects, and to 
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determine whether better results could be achieved in some 
locations versus others in terms of pain severity, flexibility, 
and quality of life.	  
METHODS 
Patient Information 
 The inclusion in this observational study (not controlled 
or randomized) was performed over 1 year but patients were 
recommended by their physicians to take Flexofytol® during 
6 months with evaluation visits after 6 weeks, 3 months and 
6 months of treatment ; patients were also allowed to 
continue or discontinue their concomitant analgesic and anti-
inflammatory therapies if they considered no more 
necessary. The diagnosis of osteoarthritis was done by X 
rays by an independent radiologist. Information was 
collected retrospectively and anonymously from the medical 
files of patients, as reported by 110 general practitioners who 
followed 820 patients treated with Flexofytol® (739 were 
using 2 capsules two times daily and 81 took 2 capsules 3 
times daily) to improve joint function. These patients were 
seen as outpatients. In order to collect a maximum amount of 
relevant information for this study, these physicians received 
explanations of the aims of this study. Ethical approval was 
not required. Physicians were requested to report relevant 
clinical parameters collected during a general outpatient 
visit, such as age, sex, and visit date. Physicians were asked 
to report patient responses regarding the effect of Flexofytol®, 
including locations of the affected joints, pain intensity at the 
various locations on a scale from 0 (no pain) to 10 
(intolerable pain), flexibility of the painful joint(s) (0=bad, 
10=excellent), and quality of life on a visual scale from 0 
(bad) to 10 (excellent). Global evaluation of the efficacy of 
treatment according to the patient, the use of concomitant 
treatments (such as analgesic and anti-inflammatory 
therapies), undesirable effects, and the wish of the patient to 
continue or discontinue the treatment were also ascertained. 
Variables were reported in the medical file at baseline and 
after 6 weeks, 3 months, and 6 months of treatment. 
Statistical Analysis 
 Data were expressed as mean ± standard deviation for 
quantitative variables and scores; categorical variables were 
expressed as numbers and percentages. For each patient and 
at each visit (baseline, 6 weeks, 3 months, and 6 months), the 
number of concomitant drugs was also calculated. All 
subjects were included in an intend-to-treat analysis. 
Longitudinal data such as pain, mobility, and quality of life 
were analyzed via the General Linear Model Method in order 
to follow the evolution of the mean when the value was 
repeated for the same subject. Differences were considered 
statistically significant at p<0.05. 
RESULTS 
General Profile of the Study 
 One hundred and ten general practitioners from Belgium 
participated in this study. In total, 820 patients suffering 
from osteoarthritis (36.7% men), with a mean age of 64.2 ± 
12.4 years, were followed. Flexofytol® was administered at a 
mean dose of 2 capsules twice daily in 739 patients (90.1%); 
the remaining patients were treated with a different dosage 
(3X2 capsules daily). The majority of patients (n=563; 
69.3%) suffered osteoarthritis at a single location, and (n=67; 
8.3%) suffered from at least three locations. The single 
locations were most frequently the knee and the lower back 
(Table 1). Before starting Flexofytol®, most patients (85%) 
were treated with non-steroidal anti-inflammatory drugs 
(54.3%), analgesic agents (64.7 %), and/or chondroprotec-
tive agents (13.4%); these compounds were combined in 
some patients. Preliminary analysis of the medical files 
revealed that most patients treated with Flexofytol® attended 
their regular follow-up visits: 85% at the 6-week visit, 80% 
at the 3-month visit, and 86% at the 6-month visit. 
Table 1. Patient demographics. 
 
 
Men  296 (36.7) 
Women  511 (63.3) 
Age  Mean ± standard deviation 790 64.2 ± 12.4 
Number of  
painful locations 
 812  
1  563 (69.3) 
2  182 (22.4) 
3+   67 (8.3) 
Most frequent  
locations  
 812  
knee  175 (21.6) 
lower back  155 (19.1) 
hip  57 (7.0) 
neck  53 (6.5) 
hand (thumb + fingers)  51 (6.3) 
shoulder  49 (6.0) 
knee + back  31 (3.8) 
neck + back  29 (3.6) 
hip + hand  28 (3.4) 
knee + hip  21 (2.6) 
other  163 (20.1) 
Effect of Flexofytol® on Clinical Parameters 
 Pain severity progressively and significantly declined in 
most patients within 6 months; the mean score fell from 6.9 
to 3.2 (p<0001; Fig. 1). The patient’s impression of 
flexibility significantly increased from a mean score of 4.2 
prior to treatment to 6.7 after 6 months of therapy 
(p<0.0001) (Fig. 1). This double improvement was 
associated with better quality of life, since the mean score 
increased from 4.7 to 6.9 within the same time period 
(p<0.0001) (Fig. 1). It is interesting to note that most of the 
reported improvement occurred within the first 6 weeks of 
therapy. 
Targets of Flexofytol® 
 Although pain severity was more intense among patients 
with osteoarthritis of the knee (p=0.003), shoulder 
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(p=0.016), or spine (p=0.0001), the analgesic effect  
of Flexofytol® was similarly reported in all these locations 
(Fig. 2). Patient perception of flexibility was less evident for 
the spine (p=0.023) but better for the hand (p=0.014), while 
clinical improvement over time was more evident for 
patients suffering from pain in the knee (p=0.0045) or in the 
hip (p=0.036; Fig. 3). Quality of life improved overt time, 
but less among patients suffering from low back pain 
(p=0.0004) or hip pain (p=0.012). This study also revealed 
that higher pain scores were associated with higher numbers 
of painful osteoarthritic lesions. More lesions were also 
associated with lower general evaluations of articular 
flexibility and quality of life. (p=0.041) (similar benefits of 
Flexofytol® were reported whether the patient suffered from 
one or more painful joints). 
 
Fig. (1). Pain reduction was associated with better mobility and 
quality of life. 
Reduction of Concomitant Treatments 
 When patients were treated with Flexofytol®, they 
significantly reduced the number of additional treatments 
they took for osteoarthritis (p<0.0001; Fig. 4). This 
phenomenon was independent from the locations of pain 
(Fig. 4). However, the consumption of concomitant therapies 
remained elevated among patients suffering from pain in the 
spine (p=0.014) or the shoulder (p=0.040). It is interesting to 
note that the reduction in the use of concomitant therapies 
was statistically significant in the first 6 weeks after the 
initiation of Flexofytol® therapy (Fig. 4 and Table 2). In 
general, Flexofytol® allowed patients to reduce the number 
of other treatments of osteoarthritis, independent of the 
number of painful locations or concomitant therapies. 
Patient Global Assessments 
 Global assessments provided by the patients confirmed 
the specific data obtained at 6 weeks after therapy initiation. 
At 6 weeks, 77.1% of patients were already satisfied with 
their use of Flexofytol®, and 79% were still satisfied at 6 
months. Accordingly, the percentage of satisfied patients 
was strikingly higher than that of patients whose pain was 
unchanged (18.9%) or had deteriorated (2.1%) at the end of 
the follow-up period. After 6 months of therapy, 41.7% of 
the patients who were seen at this visit wished to continue 
Flexofytol® for a longer period, 10.8% responded negatively, 
and 47.5% had no opinion for continuing for a longer period. 
 
Fig. (2). Targets of the analgaesic effect of Flexofytol®. 
 
Fig. (3). Improvement in flexibility was more marked for the hand. 
Undesirable Effects 
 During the follow-up period, side effects were reported 
by 3.6% of the patients at 6 weeks, by 2.5% at 3 months, and 
by 1.3% at 6 months. Most adverse events were related to 
gastrointestinal intolerance, for example diarrhoea. 
DISCUSSION 
 In the present investigation, the experience of 110 
Belgian general practitioners suggests that 2 capsules of 
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Flexofytol® taken twice daily can significantly improve the 
pain, articular flexibility, and quality of life of osteoarthritic 
patients, nearly without undesirable effects and within 6 
weeks (Fig. 1). Flexofytol® also reduced the consumption of 
concomitant therapies for osteoarthritis, such as anti-
inflammatory drugs, analgaesic drugs, and chondroprotective 
agents, and was associated with a high degree of patient 
satisfaction (Fig. 4). The clinical improvement was 
maintained at least up to 6 months despite the statistical 
reduction of concomitant analgesic and anti-inflammatory 
therapies at 6 weeks suggesting that the benefit was not 
related to the concomitant therapies. The best indications of 
Flexofytol® suggested from this study are painful 
osteoarthritis of the knee or of the hip, although benefits 
were also reported in other degenerative joint conditions 
(Fig. 2). The weakest point of this study is that it is 
observational, not randomized, not double blind and not 
placebo controlled; yet the data come from a collection of 
real-life information that reflects the experiences of 110 
physicians over 1 year and of 820 patients over 6 months of 
therapy. This approach is quite different from a randomized, 
controlled, double blind study with a reference molecule, but 
includes a large number of physicians and patients and 
covers a relatively long period of observation. It is also 
important to stress the good compliance of the treated 
patients and the proportion of patients who wished to 
continue Flexofytol® therapy longer than 6 months. The 
observed benefits at 6 weeks may be due to the anti-
inflammatory mode of action and/or analgaesic effect of 
curcumin, while patient satisfaction at 6 months may result 
from additional regenerating effects of curcumin on articular 
structures. A series of in vitro studies previously uncovered 
an anti-catabolic effect of curcumin that inhibits 
metalloproteases and stimulates the production of 
glycosaminoglycans, which play a role in the accumulation 
of aggrecans in the cartilage and reinforce the matrix; 
curcumin also promotes the formation of chondrocytes [4, 
6]. 
 
Fig. (4). Reductions in concomitant therapies were independent of 
osteoarthritis location. 
Table 2. Reduction of concomitant therapies already 
occurred within 6 weeks and was sustained at 6 
months. 
 
Time of  
Follow Up  
Mean Number (SD) of Concomitant 
Therapies Per Patient 
-Baseline  1.60 (0.73) 
-6 weeks  0.93 (0.71) 
-3 months  0.92 (0.73) 
-6 months  0.75 (0.73) 
 
 Curcumin is relatively stable in the intestine, but to detect 
curcumin in circulating plasma, dosages as high as 10-12 g 
daily are necessary. Once in the blood, curcumin can persist 
for a long time, and can penetrate the peripheral tissue due to 
its polyphenol structure [6, 7]. The curcumin extract in 
Flexofytol® is a micro-emulsion that is 1350 times more 
assimilable than native curcumin powder. In Flexofytol® 
capsules, curcumin is present in the centre of a 200-nm 
micelle constituted of polysorbate with a hydrophilic 
extremity on the periphery and a hydrophobic extremity 
oriented toward the centre. This formulation differentiates 
Flexofytol® from the other available preparations of 
curcumin, which for example use black pepper or piperidine 
as supports, or are combined with other plant extracts. The 
benefits of curcumin in osteoarthritis have been reported in 
other studies as well [6] The administration of 1 g Meriva (a 
curcumin extract coated in a phytosome to facilitate its 
resorption by the intestine) over 3-8 months also improved 
symptoms, articular function, and quality of walking; these 
benefits were associated with reductions in the levels of 
inflammation mediators such as Interleukin 1β, Interleukin 6, 
the ligand of CD40, and other adhesion molecules, as well as 
reductions in the blood sedimentation rate [8-10]. 
 Other clinical trials with different curcumin preparations 
in osteoarthritis have been recently published in the 
literature; accordingly, a double blind prospective 
randomized clinical trial has suggested a benefit of curcumin 
as an adjuvant therapy to diclofenac (75 mg daily) in primary 
knee osteoarthritis but no statistical significance [11]. First in 
a 3 month study, Meriva (a curcumin phytosome 
phosphatidyl complex) decreased pain and improved joint 
function in 50 osteoarthritis patients. In a following study in 
100 patients, Meriva also improved a series of inflammatory 
markers and sedimentation rate as well [12]. A curcuma 
domestica extract seems to be as effective as ibuprofen for 
the treatment of osteoarthritis but with fewer gastrointestinal 
adverse events [13]. A randomized double blind placebo 
control parallel group clinical trial conducted among patients 
with mild-moderate knee osteoarthritis showed a greater 
reduction of Womac, Visual analogue score and Lequesne 
pain functional index than in placebo and also on pain and 
physical function [14]. 
 In rheumatoid arthritis, BCM-95, another curcumin 
formulation, improved the disease articular score more than 
the anti-inflammatory drug diclofenac, suggesting that 
curcumin could be considered as an alternative to non-
steroidal anti-inflammatory drugs, with better tolerance; note 
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that in animal models, curcumin exerts an analgaesic effect 
[15]. 
 In conclusion, Flexofytol® like other curcumin extracts is 
appropriate for the care of patients complaining of joint 
problems. Flexofytol® may not only address painful joints, 
but may also contribute to the regeneration of cartilage. 
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